Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 15/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 15/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 15/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10194995 | 0.84 | P2RY14 (0.49) | P2RY14 | |
| SCHEMBL10194964 | 0.80 | P2RY14 (0.35) | MAP4K1P2RY14ACKR3 | |
| SCHEMBL10194871 | 0.80 | TLR9 (0.41) | TLR9TLR8TLR7P2RY14 | |
| SCHEMBL10194744 | 0.78 | TLR9 (0.43) | TLR9TLR8TLR7P2RY14 | |
| SCHEMBL10194705 | 0.76 | JAK2 (0.45) | — | |
| SCHEMBL10194956 | 0.75 | FGFR1 (0.44) | P2RY14FGFR1FLT1 | |
| SCHEMBL9959526 | 0.72 | DRD2 (0.39) | P2RY14FGFR1FLT1 | |
| SCHEMBL10194983 | 0.72 | P2RY14 (0.47) | P2RY14 | |
| SCHEMBL10194934 | 0.72 | S1PR1 (0.40) | — | |
| SCHEMBL17850463 | 0.71 | HTR2A (0.39) | P2RY14FGFR1FLT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655357-B1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | TLR9 192/4885TLR8 88/4885TLR7 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.